Active Not Recruiting PHASE2 INTERVENTIONAL 5-arm NCT05291091

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy

Sponsor: Edgewise Therapeutics, Inc.

Conditions Becker Muscular Dystrophy

Interventions Placebo Sevasemten 10 mg Sevasemten 12.5 mg Sevasemten 5 mg

Updated 32 times since 2022 Last updated: Jan 29, 2026 Started: Nov 10, 2022 Primary completion: Sep 30, 2026 Completion: Sep 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Becker Muscular Dystrophy and is currently ongoing. Edgewise Therapeutics, Inc. leads this study, which shows 32 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

32 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE2
Jan 2026 — Feb 2026 [monthly]

Active Not Recruiting PHASE2
Dec 2025 — Jan 2026 [monthly]

Active Not Recruiting PHASE2
Oct 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE2
Sep 2025 — Oct 2025 [monthly]

Active Not Recruiting PHASE2

▶ Show 27 earlier versions

Aug 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE2
Jun 2025 — Aug 2025 [monthly]

Active Not Recruiting PHASE2
May 2025 — Jun 2025 [monthly]

Active Not Recruiting PHASE2
Apr 2025 — May 2025 [monthly]

Active Not Recruiting PHASE2
Mar 2025 — Apr 2025 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Feb 2025 — Mar 2025 [monthly]

Recruiting PHASE2
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE2
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE2
Oct 2024 — Dec 2024 [monthly]

Recruiting PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Apr 2024 — Jun 2024 [monthly]

Recruiting PHASE2
Feb 2024 — Apr 2024 [monthly]

Recruiting PHASE2
Dec 2023 — Feb 2024 [monthly]

Recruiting PHASE2
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE2
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE2
Jul 2023 — Oct 2023 [monthly]

Recruiting PHASE2
Apr 2023 — Jul 2023 [monthly]

Recruiting PHASE2
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE2
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE2
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE2
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE2
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE2
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Apr 2022 — Sep 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Edgewise Therapeutics, Inc.
ImagingNMD
Medpace, Inc.
SYSNAV

Data source: Edgewise Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Auckland, New Zealand , Aurora, United States , Austin, United States , Baltimore, United States , Barcelona, Spain , Chicago, United States , Cincinnati, United States , Columbus, United States , Copenhagen, Denmark and 39 more locations